Redirecting to https://markets.businessinsider.com/news/stocks/blossomhill-therapeutics-to-present-preliminary-results-from-phase-1-dose-escalation-backfill-cohorts-in-phase-1-2-solara-trial-of-omni-egfr-inhibitor-bh-30643-in-advanced-egfr-mutant-nsclc-at-1036185558